Illumina, Inc/Pacific Biosciences of California, Inc [Archived]
Illumina, Inc/Pacific Biosciences of California, Inc [Archived]

The following Competition practice note provides comprehensive and up to date legal information covering:

  • Illumina, Inc/Pacific Biosciences of California, Inc [Archived]
  • Case facts
  • Timeline

CASE HUB

ARCHIVED–this archived case hub reflects the position at the date of the cancellation of the investigation on 3 January 2020 after the abandonment of the transaction; it is no longer maintained.

See further, timeline.

Case facts

OutlineUK merger investigation into the anticipated acquisition by Ilumina Inc, of Pacific Biosciences of California Inc. The transaction involves horizontal overlap in the market for DNA sequencing systems, which are used to study genetic variations in humans and other species for purposes such as advanced disease research and drug development.

Latest developmentsOn 2 January 2020, Illumnia Inc and Pacific Biosciences announced that they had decided not to continue with the transaction because of the length regulatory approval process the transaction had already been subject to and the continued uncertainty of the ultimate outcome. Consequently, the CMA formally cancelled its phase 2 investigation on 3 January 2020.

The CMA’s phase 2 deadline was 5 February 2020.

Parties• Illumina Inc (Ilumina), headquartered in San Diego, California, is a US-based global supplier of DNA sequencing systems to organisations across the world including UK universities, laboratories and research institutes.

• Pacific Biosciences of California Inc (PacBio) headquartered in Menlo Park, California, is a US-based global supplier of DNA sequencing systems to organisations across the world including UK universities, laboratories and research institutes.

Market(s)Supply

Popular documents